ETH-LAD Stats & Data

ETH-LAD was first described in the scientific literature by Japanese researcher Tetsukichi Niwaguchi and colleagues in 1976. Nearly a decade later, American researchers Andrew J. Hoffman and David E. Nichols conducted preclinical pharmacological studies of the compound in 1985, examining its properties as part of broader investigations into lysergamide structure-activity relationships. The effects of ETH-LAD in humans were subsequently investigated by Alexander Shulgin, with initial observations communicated via personal correspondence with Nichols in 1986. Shulgin later published his findings in a 1994 literature review and provided comprehensive documentation in his 1997 book TiHKAL (Tryptamines I Have Known and Loved), where he characterized the compound as producing distinctive visual effects compared to LSD. Shulgin also noted concerns about the compound's apparent instability in solution, observing a significant drop in potency after several months of storage even under favorable conditions. ETH-LAD remained relatively obscure outside of research contexts until it emerged as a novel designer drug in Europe around 2016. It has since been marketed alongside other lysergamides such as 1P-LSD and AL-LAD as a grey-market research chemical, commercially distributed through online vendors catering to the psychedelic research community. A prodrug variant, 1P-ETH-LAD, has also been developed and appeared on the designer drug market.

Effects aggregated from 32 experience reports (23 Erowid + 9 Bluelight)

From 20 individual dose entries

Most common forms and preparations reported

Dose relative to body weight from reports with weight data

Redosing behavior across 16 reports